Retrospektivna procjena učinka nintedaniba u mišjem modelu plućne fibroze

Q3 Veterinary
Željka Anzulović Šanta, Anja Ognjenović, F. Božić, Boška Hrvačić, Ines Glojnarić, Snježana Čužić, Maja Antolić
{"title":"Retrospektivna procjena učinka nintedaniba u mišjem modelu plućne fibroze","authors":"Željka Anzulović Šanta, Anja Ognjenović, F. Božić, Boška Hrvačić, Ines Glojnarić, Snježana Čužić, Maja Antolić","doi":"10.46419/vs.54.4.4","DOIUrl":null,"url":null,"abstract":"Pulmonary function tests (PFTs) routinely implemented in clinics are the first step in the diagnosis of idiopathic pulmonary fibrosis. Evaluation of PFTs in the mouse model of pulmonary fibrosis accompanied by histological readouts may improve the clinical predictability of new therapeutic candidates. Forced vital capacity (FVC) is considered the most predictive of restrictive pulmonary disorders. This study aimed to test the improvement of PFT in mice lung fibrosis induced by treatment with an approved substance nintedanib, considered the gold standard. The hypothesis that treatment in animal models will demonstrate similar effects as in humans in the most relevant clinical outcomes was tested. Two experimental designs were enrolled in this study, a preventive regimen, with treatment initiation from the day of the challenge; and a therapeutic regimen, starting on day 7 postchallenge when fibrotic changes are present in the lungs. Experiments were terminated at two different time points, at 14 and 21 days postchallenge. C57BL/6 mice were administered with bleomycin (BLM) intranasally and treated with nintedanib from day 0 to day 14 or from day 7 until day 21. Fourteen or 21 days after the BLM challenge, PFTs were assessed using the in vivo invasive lung function measurement system Buxco® Pulmonary Function Test (PFT) (DSI™, New Brighton, USA). Histological evaluation was performed as a modified Ashcroft score. The bleomycin challenge induced a significant decrease of FVC in both experiments. However, nintedanib treatment given in both regimens significantly improved lung functionality. These findings were confirmed with histological analysis of the Ashcroft scoring system, modified by Matsuse. In conclusion, a good correlation between functional test parameters and the clinical effect of nintedanib was shown in both experiments: the preventive regimen was sampled 14 days post-challenge and the therapeutic regimen 21 days post-challenge. Based on these findings, the implementation of PFTs could be a good platform to increase the translational value of the model and potential new treatments.","PeriodicalId":23596,"journal":{"name":"Veterinarska stanica","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinarska stanica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46419/vs.54.4.4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Veterinary","Score":null,"Total":0}
引用次数: 1

Abstract

Pulmonary function tests (PFTs) routinely implemented in clinics are the first step in the diagnosis of idiopathic pulmonary fibrosis. Evaluation of PFTs in the mouse model of pulmonary fibrosis accompanied by histological readouts may improve the clinical predictability of new therapeutic candidates. Forced vital capacity (FVC) is considered the most predictive of restrictive pulmonary disorders. This study aimed to test the improvement of PFT in mice lung fibrosis induced by treatment with an approved substance nintedanib, considered the gold standard. The hypothesis that treatment in animal models will demonstrate similar effects as in humans in the most relevant clinical outcomes was tested. Two experimental designs were enrolled in this study, a preventive regimen, with treatment initiation from the day of the challenge; and a therapeutic regimen, starting on day 7 postchallenge when fibrotic changes are present in the lungs. Experiments were terminated at two different time points, at 14 and 21 days postchallenge. C57BL/6 mice were administered with bleomycin (BLM) intranasally and treated with nintedanib from day 0 to day 14 or from day 7 until day 21. Fourteen or 21 days after the BLM challenge, PFTs were assessed using the in vivo invasive lung function measurement system Buxco® Pulmonary Function Test (PFT) (DSI™, New Brighton, USA). Histological evaluation was performed as a modified Ashcroft score. The bleomycin challenge induced a significant decrease of FVC in both experiments. However, nintedanib treatment given in both regimens significantly improved lung functionality. These findings were confirmed with histological analysis of the Ashcroft scoring system, modified by Matsuse. In conclusion, a good correlation between functional test parameters and the clinical effect of nintedanib was shown in both experiments: the preventive regimen was sampled 14 days post-challenge and the therapeutic regimen 21 days post-challenge. Based on these findings, the implementation of PFTs could be a good platform to increase the translational value of the model and potential new treatments.
临床常规肺功能测试是诊断特发性肺纤维化的第一步。在伴有组织学读数的肺纤维化小鼠模型中评估PFTs可以提高新的候选治疗药物的临床可预测性。强迫肺活量(FVC)被认为是最能预测限制性肺部疾病的指标。本研究旨在测试PFT对经批准的物质茚替达尼治疗诱导的小鼠肺纤维化的改善作用,该物质被认为是金标准。动物模型中的治疗将在最相关的临床结果中表现出与人类相似的效果,这一假设得到了检验。本研究采用了两种实验设计,一种预防方案,从激发当天开始治疗;以及治疗方案,从激发后第7天开始,此时肺部出现纤维化变化。实验在两个不同的时间点终止,即激发后14天和21天。C57BL/6小鼠从第0天至第14天或从第7天至第21天用博来霉素(BLM)鼻内给药并用茚替达尼处理。BLM激发后14或21天,使用体内侵入性肺功能测量系统Buxco®肺功能测试(PFT)(DSI)评估PFT™, 美国新布莱顿)。组织学评估作为改良的Ashcroft评分进行。博来霉素激发在两个实验中都诱导了FVC的显著降低。然而,两种方案中给予的宁替达尼治疗显著改善了肺功能。这些发现通过Matsuse修改的Ashcroft评分系统的组织学分析得到了证实。总之,在两个实验中,功能测试参数与宁替达尼的临床效果之间显示出良好的相关性:预防方案在激发后14天取样,治疗方案在激发前21天取样。基于这些发现,PFTs的实施可能是一个很好的平台,可以提高该模型的转化价值和潜在的新治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Veterinarska stanica
Veterinarska stanica Veterinary-Veterinary (all)
CiteScore
1.10
自引率
0.00%
发文量
57
期刊介绍: The goal of the journal is to provide an international platform for the publication of articles in the fields of veterinary and animal sciences, and biotechnology. The content of the journal is particularly dedicated to veterinary practitioners, but also to veterinary scientists and university professors, to encourage them to share their knowledge and experience on this platform. Manuscripts submitted to the journal may include: original scientific papers, review articles, short communications, professional articles, case reports, conference reports and literary records and reviews of new book either in Croatian or English languages.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信